-
Question: Which out of efficacy, dosage and toxicity are the most important when testing the safeness of drugs
- Keywords:
Asked by anon-220247 to Rachel on 7 Jun 2019.Question: Which out of efficacy, dosage and toxicity are the most important when testing the safeness of drugs
- Keywords:
Comments
Alex commented on :
Clinical trials for testing new drugs are carried out in phases, where each phase is looking at a different outcome as priority. The first phase of testing is usually very small scale and carried out on healthy people, as a way to test the toxicity of the drug on humans. Once this has been established to be low/acceptable, phase 2 can begin.
The second phase is usually used for both proof of concept and/or determining correct dosing. Therefore patients may be assigned different doses of the drug to determine which is best with respect to both evidence of efficacy and also keeping side effects to a minimum.
The third stage of testing is a large scale phase 3 trial (this is where my research is focused). This is where the chosen dose of the drug is conducted on a large scale, and compared with a control (e.g. a placebo, or the current standard of care on the NHS). Here, randomisation is particularly important since we are primarily measuring efficacy (how good the drug is) so it’s crucial we carry out the experiment to ensure a fair comparison. After this phase is complete, if there is evidence the drug works the drug can be submitted to regulatory approval, where the results of all the phases will be evaluated.
So in short, efficacy, toxicity and dosing are all important aspects to measure in drug trials, and approval will always be based on a combination of these things.